期刊文献+

儿童急性髓细胞性白血病细胞遗传学和分子遗传学的初步研究 被引量:2

Classical and molecular cytogenetic abnormalities of childhood acute myeloid leukemia
下载PDF
导出
摘要 目的了解儿童急性髓细胞性白血病(AML)染色体及相关融合基因的变化。方法155例AML患儿采用直接法及24h培养法制备染色体,套式逆转录聚合酶链反应(RT-PCR)检测t(8;21)易位的AML1-ETO融合基因,t(15;17)易位的PML-RARα融合基因。LSI-FISH检测MLL融合基因。结果155例AML中,异常核型101例(65·2%),各亚型的异常率为:M577·3%,M365·9%,M263·9%,M462·5%,M660·0%,M142·9%。最常见的数目异常为假二倍体59例(58·4%),最常见的结构异常为t(8;21)31例(32·7%),t(15;17)27例(26·7%),11号染色体异常10例(9·9%),并与M2、M3、M5相关。RT-PCR检测M2、M3相关的融合基因AML1-ETO及PML-RARα均发现了隐匿易位及变异异位,FISH检测11例AML患儿中的MLL基因3例阳性。结论儿童AML进行染色体分析及融合基因的检测,有助于AML诊断及亚型之间的鉴别诊断。 Objective To investigate the chromosomal abnormalities and fusion genes of childhood acute myeloid leukemia(AML). Methods AML1-ETO fusion gene derived form t (8; 21) and PML-RARα fusion gene derived form t( 15; 17) were detected with reverse transcription multiplex nested polymerase chain reaction technique(RT-multiplex nested PCR), and MLL fusion gene with LSI-FISH technique. Results Of 155 cases, 101 patients(65.2%) had cytogenefie abnormalities. The incidences of cytogenetic abnormalities in FAB subtypes were M5 77. 3 %, M3 65.9 %, M263. 9 %, M462.5%,M660%, and M142.9%. The most frequent abnormality of chromosome number was pesudodipiloid(59 cases, 58. 4%), the most frequent abnormality of chromosome structure was t(8; 21)(31 cases, 32.7%) and t(15; 17) was the second frequent aberration(27 eases, 26.7%). The abnormality of chromosome 11 was found in 10 eases(9.9%), which was associated with FAB subtypes M2, M3 and M5. Dormant and variance translocations were found when applying RT-PCR tech- nique to detect AML1-ETO fusion gene and PML-RARα fusion gene, MLL fusion gene was detected with LSI-FISH probe in 3 of 11 AML patients. Conclusion Chromosome analysis and detection of fusion genes are helpful in the diagnosis of AML and the differentiation diagnosis of AML subtype.
出处 《江苏医药》 CAS CSCD 北大核心 2007年第5期460-463,共4页 Jiangsu Medical Journal
关键词 白血病 髓性 儿童 染色体 融合基因 Leukemia Myeloid Children Chromosome Fusion genes
  • 相关文献

参考文献8

二级参考文献11

  • 1陈赛娟,曹琪,马志贵,苏欣莹,熊树民,叶菁,王振义,李秀松,沈志祥,张芬琴,孙关林,方智雯,欧阳仁荣,朱学宏,应大明,顾龙君,陈竺.急性非淋巴细胞白血病的细胞遗传学及其预后意义[J].中华血液学杂志,1996,17(2):61-63. 被引量:27
  • 2Zhang T,Leukemia,1994年,15卷,3页
  • 3陈赛娟,J Clin Invest,1993年,91卷,2206页
  • 4陈竺,Leukemia,1991年,71卷,425页
  • 5Huang M E,Blood,1988年,72卷,567页
  • 6Tien H F,Cancer Genet Cytogenet,1988年,32卷,101页
  • 7Xue Y Q,Leuk Lymphoma,1999年,33卷,581页
  • 8张之南,血液病诊断及疗效标准(第2版),1998年,168页
  • 9Xue Y Q,Cancer Gaenet Cytogenet,1996年,92卷,18页
  • 10陈赛娟,中华血液学杂志,1996年,17卷,61页

共引文献95

同被引文献26

  • 1刘怡,李志刚,赵玮,李蓓,巩文玉,吴敏媛.儿童急性淋巴细胞白血病伴有TEL-AML1融合基因表达的免疫表型特点分析[J].中国实验血液学杂志,2006,14(4):714-716. 被引量:3
  • 2Shigesada K, van-de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv ( 16 ) chimeric gene CBFB/PEBP2B-MHY11. Oncogene, 2004 ;23:4297 -4307.
  • 3Kurokawa M, Hirai H. Role of AML1/Runxl in the pathogenesis of hematological malignancies. Cancer Sci ,2003 ;94:841 - 846.
  • 4Tiensiwakul P. Cloning and sequencing of ETV6/RUNX1 ( TEL/ AML1 ) variant in acute lymphoblastic leukemia. Cancer Genet Cytogenet, 2004 ; 149:85 - 88.
  • 5Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood, 2006; 107: 4508 - 4513.
  • 6Guidez F, Petrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood, 2000; 96 : 2557 - 2561.
  • 7Chakrabarti SR, Sood R, Nandi S, et al. Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycledependent assembly into nuclear bodies. Proc Natl Acad Sci USA, 2000 ;97 : 13281 - 13285.
  • 8Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia, 1999 ; 13:6 - 13.
  • 9Uchida H, Downing JR, Miyazaki Y, et al. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene, 1999 ; 18 : 1015 - 1022.
  • 10Loh ML, Rubnitz JE. TEL/AMLl-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol, 2002 ;9:345 - 352.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部